[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kayseri City Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":289},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,45,69,93,128,157,184,216,243,267],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645047","dose-response-effect-of-intra-articular-ozone-in-knee-osteoarthritis-100645047",false,"NCT07678996","Dose-Response Effect of Intra-Articular Ozone in Knee Osteoarthritis","Dose-Response Effect of Intra-Articular Ozone in Knee Osteoarthritis: A Randomized Controlled Single-Blind Clinical Study","Inclusion Criteria:\n\n* Patients aged 40-75 years diagnosed with knee osteoarthritis according to the American College of Rheumatology 2019 criteria\n* Grade 2 or 3 knee osteoarthritis based on the Kellgren-Lawrence radiological classification system.\n* Presence of chronic knee pain lasting for more than 6 months.\n* Numerical Rating Scale score of 3 or higher during knee-loading activities\n\nExclusion Criteria:\n\n* Presence or history of acute knee infection, major knee trauma, or inflammatory arthritis\n* History of knee fracture or surgical intervention involving the affected knee joint within the last 6 months.\n* History of intra-articular injections (e.g., corticosteroids, hyaluronic acid, PRP) into the affected knee joint within the last 6 months.\n* History of physical therapy or rehabilitation in the knee region within the last 6 months\n* Presence of osteomyelitis adjacent to the knee joint, bacteremia, or hemarthrosis.\n* History of malignancy involving the lower extremity.\n* Known hypersensitivity or allergy to medical ozone.\n* Severe anemia, thrombocytopenia, active bleeding disorders, or ongoing anticoagulant therapy.\n* Pregnancy or lactation\n* Active infection\n* Severe systemic diseases (e.g., advanced cardiopulmonary disease, uncontrolled diabetes mellitus).\n* Hyperthyroidism or progressive neuromuscular disorders.\n* Cognitive impairment or inability to cooperate with the assessment tools and study protocol.","ALL","40 Years","75 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the clinical efficacy of different doses of intra-articular ozone injections combined with exercise in patients aged 40-75 diagnosed with Grade 2-3 knee osteoarthritis.\n\nThe main questions it aims to answer are:\n\n* Which intra-articular ozone doses (10 µg\u002FmL, 15 µg\u002FmL, or 20 µg\u002FmL) is most effective in improving pain and physical function in knee osteoarthritis?\n* Do combined ozone and exercise therapies provide superior clinical outcomes compared to exercise therapy alone? Researchers will compare four groups (Ozone 10 µg\u002FmL + Exercise, Ozone 15 µg\u002FmL + Exercise, Ozone 20 µg\u002FmL + Exercise and Exercise Alone) to see the dose-dependent effects of ozone therapy.\n\nParticipants will:\n\n* Complete a structured home exercise program for the duration of the study.\n* Receive 3 sessions of intra-articular ozone injections (for patients allocated to the ozone groups).\n* Participate follow-up visits for clinical and functional assessments at baseline (before the procedure), immediately after the 3rd injection session, at 1 month after the last ozone injection, and at 3 months after the last ozone injection.",[27],"Knee Osteoarthritis",[29,30,31],"osteoarthritis","ozone","knee","RECRUITING","2026-06-30",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":36},"2025-11-19",{"date":40,"type":21},"2026-11-30",{"name":42,"class":43},"Kayseri City Hospital","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100644253","comparison-of-m-tapa-and-espb-for-postoperative-pulmonary-function-after-laparoscopic-cholecystectomy-100644253","NCT07666646","Comparison of M-TAPA and ESPB for Postoperative Pulmonary Function After Laparoscopic Cholecystectomy","Comparison of the Effects of Erector Spinae Plane Block and Modified Thoracoabdominal Nerve Block Through Perichondrial Approach on Postoperative Pulmonary Function and Analgesic Consumption in Patients Undergoing Laparoscopic Cholecystectomy","Inclusion Criteria:\n\n* Patients aged 18-70 years\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Patients scheduled for elective laparoscopic cholecystectomy\n* Patients who provide written informed consent\n* Patients who are able to cooperate and perform pulmonary function tests (PFTs)\n\nExclusion Criteria:\n\n* Coagulation disorders or anticoagulant therapy contraindicating regional anesthesia\n* Infection at the planned block site\n* Known allergy to local anesthetic agents\n* Conversion to open surgery\n* Hemodynamic instability\n* Inability to cooperate with pulmonary function tests (PFTs)\n* Pre-existing severe pulmonary disease (e.g., severe chronic obstructive pulmonary disease or restrictive lung disease)\n* Chronic opioid use or opioid dependence\n* Pregnancy or breastfeeding\n* Active smokers\n* Body mass index (BMI) \\> 35 kg\u002Fm²","18 Years","70 Years",{"count":55,"type":21},60,[24],"This prospective, randomized, controlled clinical trial aims to compare the effects of two ultrasound-guided fascial plane blocks, the Erector Spinae Plane Block (ESPB) and the Modified Thoracoabdominal Nerve Block through Perichondrial Approach (M-TAPA), on postoperative pulmonary function and analgesic consumption in patients undergoing laparoscopic cholecystectomy. Laparoscopic cholecystectomy is one of the most frequently performed abdominal surgical procedures worldwide. Despite minimally invasive techniques, postoperative pain remains a significant clinical problem due to port-site trauma, pneumoperitoneum, diaphragmatic irritation, and visceral manipulation.\n\nInadequate pain control may lead to impaired respiratory mechanics, reduced mobilization, delayed recovery, and an increased risk of postoperative pulmonary complications. Postoperative pulmonary dysfunction is a common consequence of upper abdominal surgery and may persist for several days, contributing to reductions in forced vital capacity (FVC) and forced expiratory volume in one second (FEV1), which are associated with increased postoperative morbidity.\n\nAlthough opioid-based analgesia is widely used, it is associated with adverse effects such as respiratory depression, nausea, vomiting, ileus, and delayed recovery. Therefore, regional anesthesia techniques and multimodal analgesia strategies are increasingly recommended to reduce opioid consumption while improving pain control.\n\nESPB and M-TAPA are ultrasound-guided fascial plane blocks used for postoperative analgesia in abdominal surgery. ESPB provides somatic and visceral analgesia through the spread of local anesthetic affecting the spinal nerve rami, while M-TAPA targets the anterior branches of the thoracoabdominal nerves to provide extensive anterior and lateral abdominal wall analgesia.\n\nDespite their increasing use, there is limited high-quality comparative evidence evaluating the effects of ESPB and M-TAPA on postoperative pulmonary function and opioid consumption in laparoscopic cholecystectomy. This study compares these two regional anesthesia techniques in a randomized controlled design to evaluate their impact on postoperative respiratory function and analgesic requirements.",[59,60],"Pulmonary Function","Post Operative Pain Control","NOT_YET_RECRUITING","2026-06-18",{"date":64,"type":36},"2026-06-24",{"date":35,"type":21},{"date":67,"type":21},"2027-03-01",{"name":42,"class":43},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":44},"100639228","conox-guided-anesthesia-in-pediatric-adenotonsillectomy-100639228","NCT07577154","Conox-Guided Anesthesia in Pediatric Adenotonsillectomy","A Randomized Controlled Trial Evaluating the Effect of qCON\u002FqNOX-Guided Anesthesia on Clinical Outcomes in Pediatric Adenotonsillectomy","Inclusion Criteria:\n\nChildren aged 3 to 12 years ASA physical status I-II Scheduled for elective adenotonsillectomy No acute infection or systemic disease Parent or legal guardian able to provide written informed consent\n\nExclusion Criteria:\n\nSkin lesions or anatomical abnormalities preventing placement of EEG electrodes History of neurological disease, including epilepsy or neurological syndromes Body mass index above the 95th percentile for age Previous pharyngeal surgery History of anesthesia-related complications Absence of written informed consent from a parent or legal guardian","3 Years","12 Years",{"count":79,"type":21},128,[24],"This study aims to evaluate the effect of Conox (qCON\u002FqNOX)-guided anesthesia on intraoperative anesthetic drug consumption and postoperative outcomes in pediatric patients undergoing adenotonsillectomy. Conox is a non-invasive EEG-based monitoring system that provides indices of both hypnosis and nociception.\n\nIn this randomized controlled trial, children aged 3-12 years will be assigned to either a Conox-guided anesthesia group or a standard monitoring group. The primary outcome of the study is total intraoperative opioid consumption, assessed from anesthesia induction to the end of surgery. Secondary outcomes include emergence time, extubation time, postoperative agitation, pain scores, and correlation between qCON\u002FqNOX values and hemodynamic parameters.",[83,84],"Adenotonsillar Hypertrophy","Postoperative Pain","2026-05-05",{"date":87,"type":36},"2026-05-11",{"date":89,"type":36},"2026-03-01",{"date":91,"type":21},"2026-09-01",{"name":42,"class":43},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":44},"100626832","low-flow-sevoflurane-and-desflurane-anesthesia-in-laparoscopic-cholecystectomy-100626832","NCT07440758","Low-Flow Sevoflurane and Desflurane Anesthesia in Laparoscopic Cholecystectomy","The Effect of Low-Flow Sevoflurane and Low-Flow Desflurane Anesthesia on Postoperative Sore Throat in Laparoscopic Cholecystectomy Surgery","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status I-II\n* Aged between 18 and 65 years\n* Patients who provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients with a recent history of upper respiratory tract infection\n* Patients with a recent history of sore throat\n* Patients with chronic cough\n* Patients with a history of previous neck or tracheal surgery\n* Patients with predictors of difficult intubation\n* Patients with a history of difficult intubation\n* Obese patients (BMI \\> 35 kg\u002Fm²)\n* Patients with chronic respiratory diseases (asthma, COPD)\n* Pregnancy\n* Use of dexamethasone\n* Patients with hepatic impairment\n* Patients with allergy to paracetamol, tramadol, granisetron, dexamethasone, or metoclopramide\n* Patients with known allergy to halogenated anesthetic agents\n* Patients with a history of malignant hyperthermia\n* Patients with mental disorders or those unable to provide reliable assessment","65 Years",{"count":102,"type":21},70,[24],"Several studies have demonstrated that inhalational anesthetic agents such as desflurane and sevoflurane may cause varying degrees of postoperative sore throat, hoarseness, and cough in orotracheally intubated patients. However, data evaluating these outcomes under low-flow anesthesia conditions remain limited and insufficient.\n\nThis single-center, prospective, randomized controlled study will be conducted in patients aged 18-65 years, classified as American Society of Anesthesiologists (ASA) physical status I-II, who are scheduled to undergo elective laparoscopic cholecystectomy under general anesthesia and who provide written informed consent to participate in the study.\n\nThe primary objective of the study is to compare the effects of low-flow desflurane and low-flow sevoflurane anesthesia on the incidence and severity of postoperative sore throat.\n\nThe secondary outcomes include the evaluation of postoperative hoarseness and cough, the incidence of postoperative nausea and vomiting (PONV), and the total consumption of inhalational anesthetic agents.",[106,107],"Laparoscopic Cholecystectomy","Postoperative Sore Throat",[109,110,111,112,113,114,115,116,117,118,119],"Postoperative sore throat","Low-flow anesthesia","Sevoflurane","Desflurane","Laparoscopic cholecystectomy","General anesthesia","Orotracheal intubation","Endotracheal cuff pressure","Postoperative complications","Postoperative nausea and vomiting","PONV","2026-04-24",{"date":122,"type":36},"2026-04-27",{"date":124,"type":36},"2026-03-20",{"date":126,"type":21},"2026-07-30",{"name":42,"class":43},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":135,"minAge":52,"maxAge":18,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":143,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":44},"100621268","comparison-of-the-analgesic-efficacy-of-erector-spinae-plane-block-in-breast-conserving-surgery-versus-serratus-anterior-block-combined-with-additional-pecto-intercostal-ii-block-100621268","NCT07368413","Comparison of the Analgesic Efficacy of Erector Spinae Plane Block in Breast-Conserving Surgery Versus Serratus Anterior Block Combined With Additional Pecto-Intercostal II Block","Comparison of Analgesic Efficacy and Opioid Consumption of Erector Spinae Plane Block Versus Serratus Anterior Block With Additional Pecto-Intercostal II Block in Breast-Conserving Surgery","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* ASA physical status I-III\n* No history of bleeding or coagulation disorders\n* Absence of neuropathy\n* Preoperative breast region NRS score \\\u003C 4\n\nExclusion Criteria:\n\n* systemic or regional infection\n* known allergy to local anesthetics\n* Unwillingness to participate in the study","FEMALE",{"count":102,"type":21},[24],"This prospective randomized study will compare the effects of Erector Spinae Plane Block (ESPB) and Serratus Anterior Plane Block combined with Pectoral Nerve Block Type II (SAPB + PECS II) on intraoperative analgesia and postoperative opioid consumption in patients undergoing breast cancer surgery. Seventy patients (ASA I-III, aged 18-75 years) will be randomized into two groups using the sealed envelope method. Ultrasound-guided blocks will be performed preoperatively by the same anesthesiologist, with Group 1 receiving ESPB and Group 2 receiving a combined SAPB + PECS II technique performed through a single skin puncture (single needle entry site) with sequential injections into the two target fascial planes. All patients will undergo surgery under general anesthesia and receive postoperative analgesia via morphine patient-controlled analgesia. Pain scores and total opioid consumption will be statistically analyzed, with p \\\u003C 0.05 considered significant.",[140,141,142],"Pain Management in Breast Surgery","Pain After Surgery","Regional Anaesthesia",[144,145,142,146,147,148],"breast surgery","pain","Serratus Anterior Plane Block","Pectoral Nerve Block Type 2","Erector Spinae Plane Block","2026-04-20",{"date":151,"type":36},"2026-04-21",{"date":153,"type":36},"2026-04-10",{"date":155,"type":21},"2026-07-31",{"name":42,"class":43},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":164,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":173,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":183,"locationsCount":44},"100627209","qconqnox-guided-anesthesia-in-patients-undergoing-thyroidectomy-surgery-100627209","NCT07445659","qCON\u002FqNOX-Guided Anesthesia in Patients Undergoing Thyroidectomy Surgery","The Effect of qCON\u002FqNOX-Guided Anesthesia Using the Conox Monitor on Clinical Outcomes in Patients Undergoing Thyroidectomy Surgery","Inclusion Criteria:\n\n* Patients aged 18-70 years\n* Thyroidectomy cases with ASA physical status I-II\n* Patients who have provided written informed consent\n\nExclusion Criteria:\n\n* Skin lesions preventing EEG electrode placement\n* Neurological disorders (e.g., epilepsy)\n* Anticipated difficult airway",true,{"count":166,"type":21},90,[24],"The aim of this study is to evaluate the effect of using the non-invasive Conox monitor on intraoperative opioid consumption. Additionally, the study aims to assess the impact of Conox monitoring on recovery time, postoperative agitation rate, and pain scores, and to investigate the correlation between qCON and qNOX values and conventional hemodynamic parameters.",[170,171,172],"Thyroid Surgeries","Intraoperative Analgesic Use","Anesthesia Depth Monitoring",[174,175,176,177,178],"thyroid surgery","intraoperative opioid consumption","anesthesia depth monitoring","qCON","qNOX","2026-04-16",{"date":149,"type":36},{"date":153,"type":36},{"date":33,"type":21},{"name":42,"class":43},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":164,"sex":16,"minAge":52,"maxAge":18,"enrollmentInfo":192,"targetDuration":4,"studyType":194,"phases":4,"briefSummary":195,"conditions":196,"keywords":200,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":215,"locationsCount":4},"100632031","median-nerve-cross-sectional-area-and-body-weight-in-carpal-tunnel-syndrome-100632031","NCT07508397","Median Nerve Cross-Sectional Area and Body Weight in Carpal Tunnel Syndrome","The Relationship Between Ultrasonographic Median Nerve Cross-Sectional Area and Electrophysiological Severity in Carpal Tunnel Syndrome Diagnosis: The Masking Role of Body Weight","CTS-US-WEIGHT","Inclusion Criteria:\n\n* Patients aged between 18 and 75 years.\n* Clinical diagnosis of Carpal Tunnel Syndrome (CTS) based on symptoms (numbness, tingling, nocturnal pain in the median nerve distribution).\n* Electrophysiological confirmation of CTS according to the American\n* Association of Neuromuscular \\& Electrodiagnostic Medicine (AAEM) criteria.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Secondary causes of CTS (e.g., Diabetes Mellitus, Hypothyroidism, Rheumatoid -Arthritis, Chronic Renal Failure).\n* Coexisting neurological conditions (e.g., Cervical Radiculopathy,\n* Polyneuropathy, Brachial Plexopathy).\n* History of previous wrist surgery, trauma, or local corticosteroid injection within the last 6 months.\n* Pregnancy or lactation.\n* Congenital anatomical variations such as a bifid median nerve or persistent median artery (detected during USG).",{"count":193,"type":21},120,"OBSERVATIONAL","This study aims to evaluate the diagnostic accuracy of ultrasonographic measurements of the median nerve in patients with Carpal Tunnel Syndrome (CTS). While ultrasound is a common diagnostic tool, various physical factors can influence its results. The researchers will investigate how a patient's absolute body weight and Body Mass Index (BMI) affect the size of the median nerve cross-sectional area across different stages of disease severity. The goal is to determine if absolute body weight plays a 'masking' role that could lead to more precise diagnostic interpretations in clinical practice.",[197,198,199],"Carpal Tunnel Syndrome","Entrapment Neuropathies","Median Nerve Compression",[201,202,203,204,205,206,207,208],"Ultrasonography","Median Nerve","Cross-Sectional Area","Body Weight","Body Mass Index (BMI)","Electromyography","Diagnostic Accuracy","Physical and Rehabilitation Medicine","2026-03-30",{"date":211,"type":36},"2026-04-02",{"date":213,"type":21},"2026-04-01",{"date":91,"type":21},{"name":42,"class":43},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":164,"sex":135,"minAge":52,"maxAge":18,"enrollmentInfo":223,"targetDuration":4,"studyType":194,"phases":4,"briefSummary":225,"conditions":226,"keywords":229,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":240,"leadSponsor":242,"locationsCount":44},"100630559","multimodal-ultrasound-for-differentiating-lymphedema-and-lipedema-100630559","NCT07489248","Multimodal Ultrasound for Differentiating Lymphedema and Lipedema","ULTRASONOGRAPHIC EVALUATION OF LOWER EXTREMITY SKIN AND SUBCUTANEOUS TISSUE WITH QUANTITATIVE ECHOGENICITY AND ELASTOGRAPHY IN LYMPHEDEMA, LIPEDEMA, AND HEALTHY CONTROL GROUPS: A CONTROLLED CLINICAL STUDY","Inclusion Criteria:\n\nIndividuals aged 18 to 75 years.\n\nClinical diagnosis of lower extremity lymphedema (for the lymphedema group).\n\nClinical diagnosis of lower extremity lipedema (for the lipedema group).\n\nHealthy individuals with no history or clinical signs of chronic lower extremity edema (for the control group).\n\nExclusion Criteria:\n\nPresence of active local infections, such as cellulitis or erysipelas, in the lower extremities.\n\nHistory of deep vein thrombosis (DVT) or severe chronic venous insufficiency.\n\nSystemic conditions that can cause secondary edema, including congestive heart failure, chronic kidney disease, or severe hepatic impairment.\n\nPrevious surgical interventions on the affected lower extremities, including liposuction, lymphatic reconstructive surgery, or major orthopedic surgeries.\n\nActive malignancy or currently undergoing radiotherapy\u002Fchemotherapy.\n\nPregnancy or lactation.",{"count":224,"type":21},75,"The aim of this observational study is to evaluate the diagnostic value of multimodal ultrasonography in differentiating between lymphedema and lipedema. Differentiating these two chronic conditions based solely on clinical examination can be challenging due to overlapping symptoms. This study will utilize various non-invasive ultrasound techniques-including B-mode ultrasound, strain elastography, power Doppler, and quantitative ImageJ analysis-to compare tissue characteristics among patients with lymphedema, patients with lipedema, and healthy controls. The goal is to identify reliable, non-invasive imaging biomarkers that can facilitate early and accurate diagnosis, thereby optimizing patient management.",[227,228],"Lymphedema","Lipedema",[230,231,232,233,234,235],"Multimodal Ultrasonography","Strain Elastography","Differential Diagnosis","Power Doppler","ImageJ Analysis","Subcutaneous Tissue","2026-03-19",{"date":238,"type":36},"2026-03-24",{"date":236,"type":36},{"date":241,"type":21},"2026-09-15",{"name":42,"class":43},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":135,"minAge":251,"maxAge":18,"enrollmentInfo":252,"targetDuration":4,"studyType":194,"phases":4,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":264,"leadSponsor":266,"locationsCount":4},"100623910","female-osteoporosis-100623910","NCT07402772","Female Osteoporosis","Performance of the Osteoporosis Self-Assessment Tool (OST) and Osteoporosis Risk Assessment Index (ORAI) in Predicting Osteoporosis in Postmenopausal Turkish Women","OST and ORAI","Inclusion criteria:\n\n* Postmenopausal women aged 50-75\n* Patients who underwent imaging with the STRATOS DEXA device at Kayseri City Hospital\n\nExclusion criteria:\n\n* Patients younger than 50 or older than 75 years of age\n* Patients with secondary osteoporosis\n* Male patients\n* Patients with uncontrolled severe comorbid conditions\n* Patients with a history of pathological fractures","50 Years",{"count":253,"type":21},1500,"The aim of this study is to compare the Osteoporosis Risk Assessment Tool and the Osteoporosis Self-Assessment Tool with the gold standard DEXA in determining the risk of osteoporosis in the lumbar and femoral regions in female individuals in the Turkish population, and to investigate their sensitivity and specificity in the first stage of screening for the detection of female osteoporosis.",[247],[257,258,259],"female osteoporosis","OST","ORAI","2026-02-04",{"date":262,"type":36},"2026-02-11",{"date":260,"type":21},{"date":265,"type":21},"2026-07-15",{"name":42,"class":43},{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":100,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":44},"100540584","effects-of-aerobic-exercise-in-obese-patients-with-atherosclerotic-cardiovascular-disease-100540584","NCT06318741","Effects of Aerobic Exercise in Obese Patients with Atherosclerotic Cardiovascular Disease","Effects of Aerobic Exercise on Kinesiophobia, Functional Capacity and Quality of Life in Obese Patients with Atherosclerotic Cardiovascular Disease","Inclusion Criteria:\n\n1. Class 1 and class 2 obese patients with a BMI of 30 kg\u002Fm2 and above and below 40 kg\u002Fm2\n2. Patients with atherosclerotic cardiovascular disease diagnosed by angiography\n3. Women and men aged 18-65\n4. Individuals who agree to participate in the study and have received a written voluntary consent form.\n\nExclusion Criteria:\n\n1. Clinical neuromuscular diseases that limit exercise, previous diagnosis of asthma, congestive heart failure, unstable angina, uncontrolled psychiatric disease or cognitive-cognitive disorders (confirmed and diagnosed in International Classification of Disease (ICD)-10 diagnosis codes 'Schizophrenia and Psychotic states (F20, F20.0, F20.1, F20.2, F20.3, F20.4, F20.5, F20.6, F20.8, F20.9, F06.2, F23.0, F23.1, F23.2, F29) , Bipolar Disorder (F31, F31.0, F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7, F31.8, F31.9) and Substance Abuse (Patients with diagnosis code ' (Z86.4)')\n2. Presence of uncontrolled systemic diseases\n\n   * Uncontrolled hypertension,\n   * Uncontrolled diabetes mellitus,\n   * Chronic liver failure\n   * Chronic renal failure and dialysis patients\n   * Chronic obstructive pulmonary disease and asthma\n3. Malignancy\n4. Infection\n5. High fever\n6. Acute inflammatory rheumatic diseases\n7. Acute peripheral vascular diseases\n8. Smoking before exercise test\n9. Alcohol consumption before exercise test\n10. Use of medications known to affect physical performance, heart rate or metabolism (including Beta blockers)\n11. Patients without cooperation and compliance\n12. Patients who did not agree to participate in the study\n13. Patients who have been included in the cardiopulmonary rehabilitation (CPR) program in the last year\n14. With acute coronary syndrome\n15. Troponin positive\n16. Unstable angina pectoris\n17. Basic contraindications of exercise test:\n\n    * High risk unstable angina\n    * Acute Cardiac Diseases (Acute MI, Acute endocarditis, myocarditis or pericarditis, Acute pulmonary embolism, etc.)\n    * Uncontrolled arrhythmias that can disrupt the hemodynamic response\n    * Symptomatic severe aortic stenosis\n    * Decompensated heart failure\n    * Non-cardiac pathologies that will affect exercise performance and be aggravated by exercise (e.g. infection, renal failure, thyrotoxicosis).",{"count":275,"type":21},32,[24],"Obesity is classified using body mass index (BMI) (BMI ≥25 overweight, BMI ≥30 obese, BMI ≥40 morbidly obese). Obese patients are Class 1 according to BMI; BMI:30-34.9 and Class 2; BMI: It is classified as 35-39.9. Patients with classes 1 and 2 will be included in the study. Obesity can be accompanied by comorbidities such as atherosclerotic vascular and cardiac pathologies, hyperlipidemia, hypertension, coronary artery disease, diabetes mellitus, so obesity treatment should be managed multidisciplinary. The basic approach to obesity treatment is diet, exercise, medical treatment, treatment of comorbid conditions and surgery. Aerobic exercise therapy, which is one of the conservative approaches in the treatment of obesity, also has an important place in the treatment of cardiovascular diseases associated with obesity. Atherosclerotic cardiovascular disease (AKD) is one of the most important causes of morbidity and mortality worldwide. Negative changes in functional capacity, quality of life and psychosocial situations are observed due to disorders associated with this disease. Physical activity is among the modifiable risk factors in atherosclerotic diseases. However, patients have a fear of movement related to angina-like symptoms, with the thought that the symptoms may recur during exercise. Lack of physical activity due to fear of movement leads to obesity, which in turn leads to aggravation of atherosclerosis and an increase in the incidence of cardiovascular events, which negatively affects individual and psychosocial capacity. Cardiopulmonary exercise test (CPET) is a non-invasive procedure that evaluates the individual's capacity during dynamic exercise and provides diagnostic and prognostic information. CPET is based on the investigation of the respiratory system, cardiovascular system and cellular response to exercise performed under controlled metabolic conditions. It allows holistic evaluation of the response to exercise, including not only the pulmonary and cardiovascular systems but also the musculoskeletal system. Fear of movement or kinesiophobia; It is defined as a state of fear and avoidance of activity and physical movement resulting from the feeling of sensitivity to painful injury and repeated injury.",[279,280],"Obesity","Coronary Artery Disease","2024-09-06",{"date":283,"type":36},"2024-09-19",{"date":285,"type":21},"2024-10",{"date":287,"type":21},"2024-12",{"name":42,"class":43},""]